Your Guide to Type 1 Diabetes Monitoring: What to Expect After a Positive Screening

First Things First: What Does "Positive" Mean?

When screening shows your child has autoantibodies, it means their immune system has started attacking the insulin-producing cells in the pancreas. This doesn't mean they have Type 1 diabetes yet—it means they're in the early stages (Stage 1 or 2) and need careful monitoring.

Key point: Finding autoantibodies early is a good thing. It gives you and your medical team time to act before symptoms appear.

‍

[ Image place ]

‍

The Monitoring Schedule: What to Expect

The 2024 Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes provides clear recommendations for how often your child should be monitored. The schedule depends on their specific situation:

If Your Child Has ONE Autoantibody

Monitoring frequency: Every 6-12 months

What will be checked:

• Repeat autoantibody testing (to see if more autoantibodies develop)
• Fasting blood glucose or HbA1c
• Physical exam and symptom check

What you should do:

• Watch for classic symptoms (increased thirst, urination, unexplained weight loss)
• Continue regular check-ups
• Stay informed about research and screening updates

If Your Child Has MULTIPLE Autoantibodies

Monitoring frequency: Every 3-12 months (depends on age and other factors)

What will be checked:

• Blood glucose monitoring (fasting glucose, HbA1c, and possibly oral glucose tolerance test)
• Ongoing autoantibody levels
• Assessment for progression to Stage 2 or Stage 3
• Growth and development
• Psychosocial screening

More frequent monitoring (every 3-6 months) is recommended if:

• Your child is under 3 years old
• They have IA-2 autoantibody (indicates higher risk)
• Blood sugar levels are starting to change
• There are early signs of glucose abnormalities

‍

[ Image place ]

‍

What Tests and Checks to Expect

Blood Glucose Tests

Fasting Blood Glucose

• Checks blood sugar after not eating overnight
• Quick and simple test

HbA1c (Hemoglobin A1c)

• Shows average blood sugar over 2-3 months
• Helps track trends over time

Oral Glucose Tolerance Test (OGTT)

• Measures how your child's body processes sugar
• More comprehensive; typically done at specialized appointments
• May be recommended every 6-12 months for those with multiple autoantibodies

Additional Monitoring

• Continuous Glucose Monitor (CGM): Some centers may recommend using a CGM for 1-2 weeks between visits to catch subtle blood sugar patterns
• Autoantibody Retesting: Periodic checks to see if new autoantibodies appear or if levels change
• Growth and Weight: Regular tracking to catch any unexplained changes

What You Can Do at Home

While your medical team handles the clinical monitoring, you play a crucial role too:

Watch for Symptoms (But Don't Panic)

The whole point of monitoring is to catch changes before symptoms become severe. Keep an eye out for:

• Increased thirst and urination
• Unexplained weight loss despite normal eating
• Extreme fatigue or lethargy✓ Fruity-smelling breath
• Blurred vision

Important: These symptoms mean Stage 3 is approaching. Call your medical team if you notice them—don't wait for the next scheduled appointment.

Keep a Simple Log

Consider tracking:

• Any symptoms you notice
• Changes in eating or drinking habits
• Energy levels
• Any illnesses (infections can sometimes accelerate progression)

Stay Informed and Connected

• Attend all monitoring appointments
• Ask questions—your medical team expects and welcomes them
• Connect with other families in similar situations (ask your doctor about support groups)
• Stay updated on clinical trials and new treatments

Understanding Progression: What If Things Change?

The monitoring schedule helps catch if your child moves from Stage 1 to Stage 2, or from Stage 2 to Stage 3. Here's what that means:

Stage 1 → Stage 2: Blood sugar starts to show abnormalities, but still no symptoms

• Monitoring may become more frequent
• You may be offered participation in clinical trials
• Discussion about disease-modifying therapies (like teplizumab)

Stage 2 → Stage 3: Clinical diabetes with symptoms

• This is when insulin therapy begins
• Because you've been monitoring, you'll catch this early and avoid DKA
• You're already connected with a diabetes team, making the transition smoother

‍

[ Image place ]

‍

The Emotional Side of Monitoring

Living in "watching and waiting" mode is not easy. It's normal to feel anxious, frustrated, or even guilty. Here's what helps:

• Remember why you're doing this: Monitoring prevents medical emergencies and provides access to new therapies
• Focus on what you can control: Attend appointments, track symptoms, maintain healthy habits
• Lean on support: Connect with other families, talk to mental health professionals if needed
• Celebrate the wins: Every monitoring visit that shows stable results is good news

Questions to Ask Your Medical Team

At each monitoring visit:

1. "What do today's results show, and have there been any changes since last time?"
2. "Are we still on the same monitoring schedule, or should we adjust?"
3. "Are there any new clinical trials or treatment options we should consider?"
4. "What specific symptoms should prompt me to call before the next appointment?"

Looking Forward

The 2024 Consensus Guidance represents a major advance in Type 1 diabetes care. For the first time, there's a clear, evidence-based roadmap for monitoring people in the early stages of T1D. This means:

• Standardized care across different medical centers
• Better tracking of progression
• Earlier intervention opportunities
• Prevention of DKA and severe complications

As a parent with Type 1 diabetes, you already have valuable insight and experience. Combined with this structured monitoring approach, you're giving your child the best possible start—transforming Type 1 diabetes from a sudden crisis into a manageable, anticipated condition.

References

1. Wherrett, D. K., et al. (2024). Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care, 47(8), 1276-1298.
   ‍https://diabetesjournals.org/care/article/47/8/1276/156880/
2. Wherrett, D. K., et al. (2024). Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia, 67, 1276-1298.
   ‍https://link.springer.com/article/10.1007/s00125-024-06205-5
3. Breakthrough T1D. (2024). Landmark International Consensus Guidance Provides a Framework for Clinicians to Monitor Those in Early-Stage Type 1 Diabetes.
   ‍https://www.breakthrought1d.org/for-the-media/press-releases/landmark-international-consensus-guidance-provides-a-framework-for-clinicians-to-monitor-those-in-early-stage-type-1-diabetes/
4. American Diabetes Association. (2026). 14. Children and Adolescents: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1), S297-S316.
   ‍https://diabetesjournals.org/care/article/49/Supplement_1/S297/163923/
5. Sanofi. Early Autoimmune T1D Screening in Children.
   ‍https://pro.campus.sanofi/t1d/articles/importance-of-early-screening-for-autoimmune-t1d
6. Type 1 Diabetes TrialNet. Become a T1D Detective.
   ‍https://www.trialnet.org/hiddencodes